ImmunityBio

ImmunityBio launches second HIV study

ImmunityBio launched a Phase 1 trial last week to evaluate whether its interleukin-15 (IL-15) superagonist Anktiva (N-803), used alone or together with broadly neutralizing antibodies, can control HIV following the interruption of antiretroviral therapy (ART). The California company said the randomized, open-label study—sponsored by the U.S. National Institute of Allergy and Infectious Diseases—will enroll about 46 people living with HIV who have suppressed the virus with ART for…

Mentions:
ImmunityBio, HIV, NIAID, drugs
Read more
Novel HIV therapy enters Phase 2

ImmunityBio announced last week the start of a Phase 2 trial of an investigational HIV treatment “to target and inhibit” early establishment of HIV reservoirs in people with acute HIV infections. The U.S. Walter Reed Army Institute of Research launched the trial of the California-based company’s interleukin-15 (IL-15) superagonist Anktiva (N-803) in combination with antiretroviral therapy. The study will take place at the Thai Red Cross AIDS Research Centre in Bangkok, according to the press…

Mentions:
ImmunityBio, WRAIR, HIV, ARV, drugs
Read more
Covid-19 development round-up: March 19, 2021

The state of the hunt:

Moderna began clinical trials of its vaccine in children.
  New vaccines from Iran and Vietnam entered human trials, and a Cuban shot reached Phase 3.
  France limited use of AstraZeneca’s vaccine to people 55 or older.

 

Vaccines


Approved or authorized vaccines
  
AZ jab is safe, EMA reaffirms—but will uptake suffer? A European Medicines Agency (EMA) risk assessment committee concluded a preliminary review…

Mentions:
Covid-19, vaccines, drugs, Moderna, AstraZeneca, EMA, Oxford University, MHRA, AU, Pfizer, BioNTech, NIAID, BARDA, SAGE, J&J, Janssen, Ocugen, BBIL, Gamaleya Institute, IMCAS, Anhui Zhifei Longcom, CNBG, Sinopharm, CIGB, Medicago, GSK, IVAC, Meissa, CEPI, University of Hong Kong, Aeterna Zentaris, Julius Maximilians University of Würzburg, Tonix Pharmaceuticals, IDT Biologika, Takeda, Bio E, Catalent, Lonza, Halix, EC, FDA, Fiocruz, Gland Pharma, RDIF, Stelis Biopharma, Strides, Chumakov Center, Thelma Therapeutics, GC Pharma, SII, Pharmaniaga, Sinovac, Bio Farma, Biovac, ImmunityBio, World Bank, WHO, DHHS, Lilly, Gilead, University of Minnesota, GWU, Novartis, Molecular Partners, NIH, Incyte, Kintor Pharmaceuticals, SaNOtize, Corat Therapeutics, Cytocom, Ampio Pharmaceuticals, Histogen, Amerimmune, Atossa
Read more
Covid-19 development round-up: February 12, 2021

The state of the hunt:

Russia’s Sputnik V vaccine has reportedly been authorized in 26 countries.
  SAGE recommended that all countries proceed with planned rollouts of the AstraZeneca/Oxford jab, while the Africa CDC offered more cautious guidance, amid reports of low efficacy against viral variants.
  Tanzania has no plans to mount a Covid-19 immunization campaign.

 

Vaccines


Approved or authorized vaccines

SAGE backs AZ jab in all…

Mentions:
Covid-19, vaccines, drugs, WHO, SAGE, AstraZeneca, Oxford University, Africa CDC, SK Bioscience, Pfizer, BioNTech, Sinovac, Butantan Institute, Lekhim, Gamaleya Institute, EMA, CanSino, SII, Moderna, BBIL, J&J, Janssen, CureVac, Takis, Rottapharm Biotech, Razi Vaccine and Serum Research Institute, United Biomedical, Covaxx, ImmunityBio, NantKwest, FDA, Government Pharmaceutical Organization, Mahidol University, PATH, Evonik, IDT Biologika, Biological E, CNBG, Sinopharm, Wockhardt, EC, Providence Therapeutics, UNICEF, COVAX, COVAX AMC, AU, AVATT, Siam Bioscience, Lilly, EUAs, mAbs, Regeneron, Gilead, Roche, ASM, NIH, Synairgen, Corvus Pharmaceuticals, Veru, Eiger BioPharmaceuticals, Ichilov Hospital
Read more
Covid-19 development round-up: January 22, 2021

The state of the hunt:

COVAX has inked a deal for up to 40 million doses of Pfizer/BioNTech’s vaccine.
  India launched its mass vaccination campaign against Covid-19.
  China and India are both giving away vaccine doses to their neighbors.

 

Vaccines


Approved or authorized vaccines
 
China’s Sinovac jab more effective using three-week interval: A silver lining has emerged to last week’s middling news from the Butantan Institute’s…

Mentions:
Covid-19, vaccines, drugs, diagnostics, COVAX, Pfizer, BioNTech, Sinovac, Butantan Institute, EU, EMA, União Química Farmacêutica Nacional, Gamaleya Institute, AstraZeneca, Dr. Reddy’s, BBIL, Moderna, Takeda, CNBG, Sinopharm, Novavax, Emergent, J&J, Janssen, Chumakov Center, iosBio, ImmunityBio, Vector Institute, EuBiologics, WUSTL, Gritstone Oncology, NIAID, ConserV Bioscience, LLNL, UN, WHO, COVAX Facility, EC, Gavi, AU, SII, Biovac, Bayer, CureVac, EUL, Oxford, CanSino, UNICEF, Africa CDC, CDC, Lilly, FDA, NIH, Roche, Turn Therapeutics, Faron Pharmaceuticals, DoD, Jemincare, AvantGen, IGM Biosciences, FIND, UNITAID, Premier Medical, Thermo Fisher, Mesa Biotech
Read more
Covid-19 development round-up: October 16, 2020

The state of the hunt:

Remdesivir showed “little or no effect” on 28-day mortality or the duration of hospital stay among hospitalized Covid-19 patients, according to data from a WHO study.
  J&J paused all dosing in trials involving its Janssen subsidiary’s vaccine candidate.
  Pfizer will not apply for U.S. FDA Emergency Use Authorization for its mRNA Covid-19 vaccine candidate before the third week of November.

 

Vaccines

Phase 3 candidates:…

Mentions:
Covid-19, vaccines, drugs, diagnostics, Gilead, WHO, Pfizer, BioNTech, mRNA, J&J, Janssen, Vector Center, AstraZeneca, SII, CNBG, RDIF, Dr. Reddy’s Laboratories, Sinovac, BBIL, IDT Biologika, DZIF, Imperial College London, Medigen, Dynavax, Vaxart, ImmunityBio, Siam Bioscience, CanSino, TTY Biopharm, CEPI, Bio Farma, Cytiva, BARDA, Epygen, Dyadic, EuBiologics, NIH, CDC, IMV, Translate Bio, Sanofi, Gavi, COVAX, DARPA, Moderna, Novavax, NIAID, Fujifilm Toyama, Recipharm, Daewoong, Merck, Lilly, Celltrion, Apogenix, Enlivex, Cue Health, DoD, Roche, Siemens, Africa CDC, BMGF, ICER
Read more
Covid-19 development round-up: June 5, 2020


The state of the hunt: 

Gavi launched an advance market commitment for Covid-19 vaccines with a $2 billion funding target. Gavi also kicked off a worldwide pooled procurement mechanism for coronavirus vaccines. CEPI announced an investment of up to $383 million in a partnership with AstraZeneca to support manufacturing of the company’s vaccine candidate for distribution by the Gavi-led procurement facility.

 

Vaccines

Existing candidates:
 
The…

Mentions:
Covid-19, vaccines, drugs, diagnostics, Gavi, AstraZeneca, CEPI, SII, Lemann Foundation, NIAID, Moderna, BARDA, Lonza, CSL, University of Queensland, J&J, Merck, Pfizer, CNBG, Inovio, Novavax, AGC Biologics, WRAIR, Rottapharm, Takis, ImmunityBio, NantKwest, Heat Biologics, Chimeron Bio, George Mason University, Codiac Bio, Ragon Institute, iBio, Smorodintsev, Institute of Experimental Medicine, Nanolek, CanSino, Emergent, Lilly, AbCellera, Gilead, TFDA, Genentech, Roche, AbbVie, Harbour BioMed, CalciMedica, I-Mab, Celltrion, BerGenBio, UCB, Sun Pharma, Organicell, NIH, SEEK Group, RDIF, WHO, Sanofi, Cambridge, Siemens Healthineers, University of Maryland, CDC
Read more
Subscribe to ImmunityBio